WNT1 and breast cancer: Increased expression of the Cancer Stem Cell (CSC) marker SOX2 in human breast cancer activates Wnt-1 signaling to promote resistance to tamoxifen, the most common therapy for Estrogen Receptor-positive (ER+) breast cancer [6].